$DAWN
Day One Biopharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023006269 Filed on March 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.03M $16.72M $61.29M
YoY Change 41.44% 55.04% 110.2%
% of Gross Profit
Research & Development $27.83M $26.02M $85.62M
YoY Change 85.48% 132.55% 96.44%
% of Gross Profit
Depreciation & Amortization $6.000K $15.00K $63.00K
YoY Change 0.0% 200.0% 215.0%
% of Gross Profit
Operating Expenses $45.86M $42.74M $146.9M
YoY Change 65.26% 94.51% 101.96%
Operating Profit -$45.86M -$146.9M
YoY Change 65.26% 101.96%
Interest Expense $3.466M $2.660M $4.746M
YoY Change 173200.0% 11465.22% 118550.0%
% of Operating Profit
Other Income/Expense, Net -$4.000K -$26.00K -$18.00K
YoY Change 300.0% -285.71% 20.0%
Pretax Income -$42.39M -$40.11M -$142.2M
YoY Change 52.78% 82.83% 95.43%
Income Tax
% Of Pretax Income
Net Earnings -$42.39M -$40.11M -$142.2M
YoY Change 52.78% 82.83% 95.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.59 -$2.17
Diluted Earnings Per Share -$0.59 -$0.56 -$2.17
COMMON SHARES
Basic Shares Outstanding 73.59M 73.55M 65.47M
Diluted Shares Outstanding 71.97M 65.47M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $318.2M $342.3M $342.3M
YoY Change 21.1% 20.39% 20.39%
Cash & Equivalents $49.27M $85.26M
Short-Term Investments $268.9M $257.0M $257.0M
Other Short-Term Assets $322.4M $5.605M $5.605M
YoY Change 20.58% -98.06% 10.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $322.4M $347.9M $347.9M
YoY Change 20.58% 20.22% 20.22%
LONG-TERM ASSETS
Property, Plant & Equipment $72.00K $20.00K $719.0K
YoY Change 9.09% -64.91% 153.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $487.0K $469.0K $469.0K
YoY Change 195.15% 177.51% 177.51%
Other Assets
YoY Change
Total Long-Term Assets $1.175M $1.188M $1.188M
YoY Change 185.89% 162.25% 162.25%
TOTAL ASSETS
Total Short-Term Assets $322.4M $347.9M $347.9M
Total Long-Term Assets $1.175M $1.188M $1.188M
Total Assets $323.6M $349.1M $349.1M
YoY Change 20.83% 20.44% 20.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.657M $260.0K $260.0K
YoY Change 564.34% -85.09% -85.09%
Accrued Expenses $17.68M $15.95M $16.18M
YoY Change 149.38% 137.74% 137.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.85M $16.62M $16.61M
YoY Change 179.45% 91.93% 91.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $408.0K $408.0K
YoY Change 2450.0% 2450.0%
Total Long-Term Liabilities $300.0K $408.0K $408.0K
YoY Change 2450.0% 2450.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.85M $16.62M $16.61M
Total Long-Term Liabilities $300.0K $408.0K $408.0K
Total Liabilities $23.15M $17.02M $17.02M
YoY Change 183.12% 96.28% 96.28%
SHAREHOLDERS EQUITY
Retained Earnings -$312.1M -$269.7M
YoY Change 101.03% 111.53%
Common Stock $7.000K $7.000K
YoY Change 16.67% 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $300.4M $332.0M $332.0M
YoY Change
Total Liabilities & Shareholders Equity $323.6M $349.1M $349.1M
YoY Change 20.83% 20.44% 20.44%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$42.39M -$40.11M -$142.2M
YoY Change 52.78% 82.83% 95.43%
Depreciation, Depletion And Amortization $6.000K $15.00K $63.00K
YoY Change 0.0% 200.0% 215.0%
Cash From Operating Activities -$25.99M -$35.31M -$109.9M
YoY Change 20.51% 168.13% 126.36%
INVESTING ACTIVITIES
Capital Expenditures $26.00K $0.00 $26.00K
YoY Change 73.33%
Acquisitions
YoY Change
Other Investing Activities -$11.17M -$2.210M -$255.0M
YoY Change 3088.1%
Cash From Investing Activities -$11.19M -$2.210M -$255.1M
YoY Change 74520.0% 3088.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $161.6M
YoY Change -3.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.184M 1.918M 165.9M
YoY Change 503.14% -44.16%
NET CHANGE
Cash From Operating Activities -25.99M -35.31M -109.9M
Cash From Investing Activities -11.19M -2.210M -255.1M
Cash From Financing Activities 1.184M 1.918M 165.9M
Net Change In Cash -35.99M -35.60M -199.0M
YoY Change 66.81% 177.04% -182.74%
FREE CASH FLOW
Cash From Operating Activities -$25.99M -$35.31M -$109.9M
Capital Expenditures $26.00K $0.00 $26.00K
Free Cash Flow -$26.01M -$35.31M -$109.9M
YoY Change 20.54% 168.13% 126.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001845337
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001845337
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40431
CY2022 dei Entity Registrant Name
EntityRegistrantName
DAY ONE BIOPHARMACEUTICALS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2415215
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2000 Sierra Point Parkway
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 501
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
484-0899
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
DAWN
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
697900000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73587094
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
San Mateo, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85262000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
284309000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
257007000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5605000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5059000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
347874000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
289368000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
699000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
227000
CY2022Q4 dawn Deposits And Other Longterm Assets Non Current
DepositsAndOtherLongtermAssetsNonCurrent
469000
CY2021Q4 dawn Deposits And Other Longterm Assets Non Current
DepositsAndOtherLongtermAssetsNonCurrent
169000
CY2022Q4 us-gaap Assets
Assets
349062000
CY2021Q4 us-gaap Assets
Assets
289821000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
260000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15950000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6709000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
405000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
204000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16615000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8657000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
408000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16000
CY2022Q4 us-gaap Liabilities
Liabilities
17023000
CY2021Q4 us-gaap Liabilities
Liabilities
8673000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73458176
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73458176
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61952292
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61952292
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
601771000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
408629000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-71000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269668000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127487000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
332039000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
281148000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
349062000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
289821000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85618000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43584000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9100000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61291000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29159000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4682000
CY2022 us-gaap Operating Expenses
OperatingExpenses
146909000
CY2021 us-gaap Operating Expenses
OperatingExpenses
72743000
CY2020 us-gaap Operating Expenses
OperatingExpenses
13782000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-146909000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-72743000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-13782000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4746000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-30000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
CY2022 dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
0
CY2021 dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
0
CY2020 dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
-30000000
CY2022 us-gaap Profit Loss
ProfitLoss
-142181000
CY2021 us-gaap Profit Loss
ProfitLoss
-72754000
CY2020 us-gaap Profit Loss
ProfitLoss
-43843000
CY2022 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
0
CY2021 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-2109000
CY2020 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-3336000
CY2022 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
0
CY2021 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
99994000
CY2020 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
0
CY2022 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-142181000
CY2021 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-170639000
CY2020 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-40507000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.17
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.62
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.62
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.33
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.33
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65466773
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65466773
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36960569
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36960569
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5529519
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5529519
CY2022 us-gaap Profit Loss
ProfitLoss
-142181000
CY2021 us-gaap Profit Loss
ProfitLoss
-72754000
CY2020 us-gaap Profit Loss
ProfitLoss
-43843000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-71000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
0
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
0
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-142252000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72754000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43843000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10673000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
526000
CY2020 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
3551000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-40507000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-54205000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
221721000
CY2021 dawn Conversion Of Redeemable Noncontrolling Interest To Common Stock Values
ConversionOfRedeemableNoncontrollingInterestToCommonStockValues
3593000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167045000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
318000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13321000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70645000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
281148000
CY2022 dawn Common Stock Issued Pursuant To Follow On Offering Net Of Issuance Costs Amount
CommonStockIssuedPursuantToFollowOnOfferingNetOfIssuanceCostsAmount
161610000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3649000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
642000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27242000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-71000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-142181000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
332039000
CY2022 us-gaap Profit Loss
ProfitLoss
-142181000
CY2021 us-gaap Profit Loss
ProfitLoss
-72754000
CY2020 us-gaap Profit Loss
ProfitLoss
-43843000
CY2022 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
0
CY2021 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
8000000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27242000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13321000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
526000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000
CY2022 us-gaap Interest Income Securities Corporate Debt Operating
InterestIncomeSecuritiesCorporateDebtOperating
2030000
CY2021 us-gaap Interest Income Securities Corporate Debt Operating
InterestIncomeSecuritiesCorporateDebtOperating
0
CY2020 us-gaap Interest Income Securities Corporate Debt Operating
InterestIncomeSecuritiesCorporateDebtOperating
0
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
468000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
179000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
139000
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
30000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
30000000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
546000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3717000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1336000
CY2022 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
300000
CY2021 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
62000
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
107000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1484000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1542000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
132000
CY2022 dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
9241000
CY2021 dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5114000
CY2020 dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1127000
CY2022 dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-347000
CY2021 dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-182000
CY2020 dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-173000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109874000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48539000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13489000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
394206000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
139158000
CY2021 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0
CY2020 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92000
CY2022 dawn Payments To Acquire Process Research And Development Assets
PaymentsToAcquireProcessResearchAndDevelopmentAssets
0
CY2021 dawn Payments To Acquire Process Research And Development Assets
PaymentsToAcquireProcessResearchAndDevelopmentAssets
8000000
CY2020 dawn Payments To Acquire Process Research And Development Assets
PaymentsToAcquireProcessResearchAndDevelopmentAssets
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-255074000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161610000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
167045000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3649000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
642000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
318000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165901000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
297120000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29977000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-199047000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
240581000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16396000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
284309000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43728000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27332000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85262000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
284309000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43728000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
940000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
545000
CY2022 dawn Transfers To Redeemable Convertible Noncontrolling Interest
TransfersToRedeemableConvertibleNoncontrollingInterest
0
CY2021 dawn Transfers To Redeemable Convertible Noncontrolling Interest
TransfersToRedeemableConvertibleNoncontrollingInterest
0
CY2020 dawn Transfers To Redeemable Convertible Noncontrolling Interest
TransfersToRedeemableConvertibleNoncontrollingInterest
3551000
CY2022 dawn Exchange Of Preferred Common And Incentive Shares In Connection With The Conversion
ExchangeOfPreferredCommonAndIncentiveSharesInConnectionWithTheConversion
0
CY2021 dawn Exchange Of Preferred Common And Incentive Shares In Connection With The Conversion
ExchangeOfPreferredCommonAndIncentiveSharesInConnectionWithTheConversion
224892000
CY2020 dawn Exchange Of Preferred Common And Incentive Shares In Connection With The Conversion
ExchangeOfPreferredCommonAndIncentiveSharesInConnectionWithTheConversion
0
CY2022 dawn Exchange Of Redeemable Convertible Noncontrolling Interest To Shares Of Common Stock
ExchangeOfRedeemableConvertibleNoncontrollingInterestToSharesOfCommonStock
0
CY2021 dawn Exchange Of Redeemable Convertible Noncontrolling Interest To Shares Of Common Stock
ExchangeOfRedeemableConvertibleNoncontrollingInterestToSharesOfCommonStock
3592000
CY2020 dawn Exchange Of Redeemable Convertible Noncontrolling Interest To Shares Of Common Stock
ExchangeOfRedeemableConvertibleNoncontrollingInterestToSharesOfCommonStock
0
CY2021Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167000000.0
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17000000.0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4719605
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
2.325-for-1
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of credit risk and other risks and uncertainties</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company’s cash, cash equivalents and short-term investments are held in more than one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institutions that the Company's cash, cash equivalents and short-term investments are held at are financially sound and, accordingly, minimal credit risk exists with respect to the financial institutions.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of its operations: ability to obtain future financing; regulatory requirements for approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; development of sales channels; protection of the Company’s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; changes to the market landscape; and the Company’s ability to attract and retain employees necessary to support its growth.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p>
CY2022 dawn Patent Costs Policytextblock
PatentCostsPolicytextblock
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty of the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations.</span></p>
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
300642000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
300572000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
300642000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
300572000
CY2022Q4 dawn Available For Sale Securitie Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
167633000
CY2022Q4 dawn Available For Sale Securitie Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritieContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
-108000
CY2022Q4 dawn Available For Sale Securities Continuous Unrealized Loss Position More Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThanTwelveMonthsFairValue
0
CY2022Q4 dawn Available For Sale Securities Continuous Unrealized Loss Position More Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAccumulatedLoss
0
CY2022Q4 dawn Available For Sale Securitie Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritieContinuousUnrealizedLossPositionAccumulatedLoss
167633000
CY2022Q4 dawn Available For Sale Securitie Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritieContinuousUnrealizedLossPositionFairValue
-108000
CY2022Q4 dawn Available For Sale Securities Gross Unrealized Gain Loss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
0
CY2022Q4 dawn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3007000
CY2021Q4 dawn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2099000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1592000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1945000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1006000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1015000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5605000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5059000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
93000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000
CY2022 us-gaap Depreciation
Depreciation
63000
CY2021 us-gaap Depreciation
Depreciation
20000
CY2020 us-gaap Depreciation
Depreciation
16000
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3336000
CY2022Q4 dawn Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
7554000
CY2021Q4 dawn Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3308000
CY2022Q4 dawn Accrued Payroll Related Expenses
AccruedPayrollRelatedExpenses
6129000
CY2021Q4 dawn Accrued Payroll Related Expenses
AccruedPayrollRelatedExpenses
2565000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2088000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
732000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
179000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15950000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6709000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
458000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
424000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
882000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
69000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
813000
CY2018Q4 dawn Number Of Directors Entitled To Be Elected By The Holders Of Common Stock
NumberOfDirectorsEntitledToBeElectedByTheHoldersOfCommonStock
200
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11061049
CY2022 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0
CY2020 us-gaap Profit Loss
ProfitLoss
-43843000
CY2021 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
99994000
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2109000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27242000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13321000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
526000
CY2022 us-gaap Profit Loss
ProfitLoss
-142181000
CY2021 us-gaap Profit Loss
ProfitLoss
-72754000
CY2020 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0
CY2022 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-142181000
CY2021 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-170639000
CY2020 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-40507000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.17
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.62
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.62
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.33
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.33
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65466773
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65466773
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36960569
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36960569
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5529519
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5529519
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10243334
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8948010
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27157040
dawn Adjustment To Additional Paid In Capital Loss On Conversion Of Temporary Equity Into Permanent Equity
AdjustmentToAdditionalPaidInCapitalLossOnConversionOfTemporaryEquityIntoPermanentEquity
100000000.0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.023
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.144
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.014
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.226
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.215
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.101
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.007
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.031
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2022Q4 dawn Deferred Tax Assets Federal And State Net Operating Loss Carryforwards
DeferredTaxAssetsFederalAndStateNetOperatingLossCarryforwards
25884000
CY2021Q4 dawn Deferred Tax Assets Federal And State Net Operating Loss Carryforwards
DeferredTaxAssetsFederalAndStateNetOperatingLossCarryforwards
17270000
CY2020Q4 dawn Deferred Tax Assets Federal And State Net Operating Loss Carryforwards
DeferredTaxAssetsFederalAndStateNetOperatingLossCarryforwards
7732000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14908000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6653000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3670000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
731000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2562000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2188000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2133000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1803000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
709000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
235000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53943000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23837000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8698000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
149000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
59000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
97000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53794000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23778000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8601000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
30000000.0
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15200000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4400000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
117600000
CY2022Q4 us-gaap Loss Contingency Accrual Insurance Related Assessment Premium Tax Offset
LossContingencyAccrualInsuranceRelatedAssessmentPremiumTaxOffset
8200000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1141000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
188000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
726000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
916000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
953000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
186000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
248000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2535000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1141000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
188000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 dawn Net Operating Loss Carryback Period
NetOperatingLossCarrybackPeriod
P12M
CY2022 dawn Defined Contribution Plan Employer Matching Contribution
DefinedContributionPlanEmployerMatchingContribution
800000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-006269-index-headers.html Edgar Link pending
0000950170-23-006269-index.html Edgar Link pending
0000950170-23-006269.txt Edgar Link pending
0000950170-23-006269-xbrl.zip Edgar Link pending
dawn-20221231.htm Edgar Link pending
dawn-20221231.xsd Edgar Link pending
dawn-20221231_def.xml Edgar Link unprocessable
dawn-20221231_lab.xml Edgar Link unprocessable
dawn-20221231_htm.xml Edgar Link completed
dawn-ex21_1.htm Edgar Link pending
dawn-ex23_1.htm Edgar Link pending
dawn-ex31_1.htm Edgar Link pending
dawn-ex31_2.htm Edgar Link pending
dawn-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img11745238_0.jpg Edgar Link pending
img11745238_1.jpg Edgar Link pending
img11745238_10.jpg Edgar Link pending
img11745238_11.jpg Edgar Link pending
img11745238_12.jpg Edgar Link pending
img11745238_13.jpg Edgar Link pending
img11745238_14.jpg Edgar Link pending
img11745238_15.jpg Edgar Link pending
img11745238_16.jpg Edgar Link pending
img11745238_17.jpg Edgar Link pending
img11745238_2.jpg Edgar Link pending
img11745238_3.jpg Edgar Link pending
img11745238_4.jpg Edgar Link pending
img11745238_5.jpg Edgar Link pending
img11745238_6.jpg Edgar Link pending
img11745238_7.jpg Edgar Link pending
img11745238_8.jpg Edgar Link pending
img11745238_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dawn-20221231_cal.xml Edgar Link unprocessable
dawn-20221231_pre.xml Edgar Link unprocessable